Avastin.net

Regression of tumour vasculature by Avastin increases tumour response

• Preclinical studies of Avastin have reported significant reductions in tumour vascular volume and density.^5,8

• The removal of tumour vasculature prevents the delivery of oxygen and nutrients to regions of the tumour, arresting tumour growth and potentially inducing shrinkage
  • in a preclinical study, VEGF blockade significantly reduced MVD, resulting in regression of both tumours and metastases.¹⁴
   
  
• In clinical trials, vascular regression by Avastin has translated into significant improvements in tumour response to therapy.^15–21

Response rates are significantly increased with Avastin in phase III clinical trials^15–21